Who
Patrick G. Enright
Director
Company insider
Files Form 4 as: Director and 10% owner, Jazz Pharmaceuticals; Director, Zenas BioPharma; Director, BioAge Labs; Director and 10% owner, Vera Therapeutics; Director and 10% owner, Veradermics; Director, Aptinyx; 10% owner, Sierra Oncology; 10% owner, Eargo.
In numbers
- Trades disclosed
- 551
- Buys
- 25
- Sells
- 76
- Bought
- $125.8M
- Sold
- $363.7M
- Companies
- 14
- Companies where not an officer
- 14
- First trade
- 3 Mar 2006
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $3,42514 at $244.64 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $408K1,692 at $241.39 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $3,42514 at $244.64 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $408K1,692 at $241.39 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —1,605 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —1,605 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,084 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,084 at $0.00 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Code C | —1,236,631 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Code C | —1,171,121 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Code C | —1,171,121 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,236,631 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,171,121 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,171,121 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $3.3M192,647 at $17.00 | filing |
| 5 Feb 2026filed 5 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $15.0M882,353 at $17.00 | filing |
The newest 500 lines are listed; the numbers count every line.
News
No headline names them, or the companies they trade most, lately.